18 February, 2015
Chordate Medical has been granted a Canadian patent covering a device for stimulation of tissue in the nasal cavity. We continue to strengthen our global IP protection of the technology that forms the base for current and future Chordate products. Our IP Insurance enable us to protect our patents from infringement.
If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.
For questions about Chordate's share price or other investment-related topics, please see if the answer is here.
For questions about the medical effects of the K.O.S treatment, please see if the answer is here.
To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.